- Home
- CEPS vs TNYA Comparison
CEPS vs TNYA Comparison
Compare CEPS & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEPS | TNYA |
|---|---|---|
| Founded | 2021 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.0M | 153.2M |
| IPO Year | 2026 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CEPS | TNYA |
|---|---|---|
| Price | $10.20 | $0.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.20 |
| AVG Volume (30 Days) | 30.5K | ★ 2.9M |
| Earning Date | 01-01-0001 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.05 | $0.52 |
| 52 Week High | $10.45 | $2.04 |
Technical Indicators
Market Signals| Indicator | CEPS | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 36.86 | 33.41 |
| Support Level | $10.05 | $0.53 |
| Resistance Level | $10.24 | $0.81 |
| Average True Range (ATR) | 0.03 | 0.03 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 0.00 | 9.15 |
Price Performance
Historical ComparisonAbout CEPS Cantor Equity Partners VI Inc. Class A Ordinary Shares
Cantor Equity Partners VI Inc is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.